NSCLC

This study tests a new drug called EP0031 in people with advanced cancers that have a specific genetic change (RET alteration), including non-small cell lung cancer. The trial has two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. About 265 adult…

This early-phase study tests a new drug called SLV-154 in about 70 people with advanced solid tumors (like head and neck, lung, breast, or ovarian cancer) that have spread. The main goal is to find a safe dose and check for side effects. Researchers will also watch for any signs …

This early study will test a personalized mRNA vaccine (RGL-270) given together with standard immunotherapy drugs in 40 people with advanced non-small cell lung cancer. The vaccine is custom-made to target unique markers on each person's tumor. The main goal is to check safety an…

This Phase 3 trial tests whether adding a maintenance drug (sacituzumab tirumotecan) after initial chemo-immunotherapy improves survival in people with metastatic squamous non-small cell lung cancer. About 851 participants will receive pembrolizumab plus chemotherapy, then either…

This study tests whether combining experimental RAS(ON) inhibitors with ivonescimab (an immunotherapy) can shrink or control advanced solid tumors that have a RAS mutation. About 370 adults with cancers like non-small cell lung cancer or colorectal cancer will receive these drugs…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This phase 2 trial is testing whether adding common diabetes drugs (metformin or rosiglitazone) to standard immunotherapy (nivolumab or pembrolizumab) can improve treatment for several advanced solid tumors, including melanoma, lung cancer, and liver cancer. About 72 participants…

This phase 2 trial tests a combination of two drugs—lucankizumab and goleirex—as a first treatment for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The study will enroll 43 participants to see if the combo shrinks tumors and how safe it …

This Phase 3 trial is testing a new oral drug called daraxonrasib (RMC-6236) against the standard chemotherapy docetaxel in about 590 people with advanced non-small cell lung cancer that has a specific RAS mutation. Participants must have already tried at least one prior treatmen…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This study tests an experimental drug called REGN5093 in people with advanced non-small cell lung cancer that has a specific change in the MET gene. The first part finds a safe dose, and the second part checks if the drug can shrink tumors. About 231 participants will take part.

This study investigates whether a lower dose of two chemotherapy drugs (carboplatin and nab-paclitaxel) combined with a delayed dose of the immunotherapy serplulimab can effectively treat advanced squamous non-small cell lung cancer. The trial compares this gentler regimen to a s…

This phase 2 trial tests a combination of three drugs (tislelizumab, anlotinib, and nab-paclitaxel) given before surgery to people with stage III non-small cell lung cancer. The goal is to see if this approach can eliminate or greatly reduce the tumor before it is removed. The st…

This early-phase study tests an experimental drug called OKN4395, taken as a pill, alone or together with the immunotherapy pembrolizumab. The goal is to find a safe dose and see if the combination can shrink tumors in people with advanced solid cancers like lung, colorectal, sto…

This study tests a new treatment using a patient's own immune cells, called CAR T cells, that are specially designed to target and kill solid tumor cells while leaving healthy cells unharmed. It is for adults with certain advanced cancers, including lung, colon, pancreatic, ovari…

This early-phase trial tests a new drug that delivers radiation directly to cancer cells carrying a specific protein called GRPR. The study includes 48 adults with advanced cancers like prostate, breast, lung, or colon cancer that have not responded to standard treatments. The ma…

This early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…

This early-phase study tests a new drug called BBO-11818 in people with advanced cancers that have a KRAS mutation, including lung, pancreatic, and colorectal cancers. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. Abou…

This early-phase trial is testing a new oral drug called RMC-5127, alone or combined with other drugs, in adults with advanced solid tumors that have a specific KRAS G12V mutation. The study includes people with lung, colorectal, and pancreatic cancers who have already tried stan…

This study tests whether a lower dose of chemotherapy combined with an immunotherapy drug can be a safer and still effective first treatment for older adults (70+) or those who are frail with advanced non-small cell lung cancer. The main goal is to see if fewer people have to sto…

This study tests whether removing only part of a lung lobe (sub-lobectomy) is as good as removing the whole lobe (lobectomy) in people with stage IIA-IIIB non-small cell lung cancer who have already received chemotherapy plus immunotherapy. About 585 participants will be randomly…

This trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…

This study tests an experimental oral drug called STX-721 in people with advanced non-small cell lung cancer that has specific EGFR or HER2 gene mutations. The trial has three parts: first finding a safe dose, then confirming the best dose, and finally expanding to more participa…

This early-phase study tests a new cell therapy called NK510 in 12 people with advanced non-small cell lung cancer that no longer responds to PD-1 inhibitors. The treatment uses specially designed natural killer cells that are blocked from a protein called TIGIT, aiming to boost …

This study tests a new oral drug, TNG462, combined with other treatments for people with pancreatic or non-small cell lung cancer that has lost the MTAP gene and, in some cases, has a RAS mutation. The trial has two phases: first to find the safest dose, then to see how well the …

This study looks at whether adding a precise radiation dose to liver tumors can make standard immunotherapy work better for people with stage IV non-small cell lung cancer. About 68 adults whose cancer has spread to the liver will either get standard drug therapy alone or standar…

This early-phase study is testing whether a combination of low-dose radiation to the whole brain, an immunotherapy drug (PD-1 inhibitor), and chemotherapy given directly into the spinal fluid can safely treat lung cancer that has spread to the lining of the brain and spinal cord.…

This early-stage trial tests an experimental drug called BBO-8520 in 350 people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The drug is taken as a pill and aims to block cancer growth. The study will check for safety, side effects, and…

This phase 3 trial is testing whether adding an extra immunotherapy drug (tremelimumab) and more chemotherapy to the standard treatment (durvalumab) can lower the amount of cancer DNA found in the blood of people with stage III non-small cell lung cancer. The study enrolls 48 par…

This study is for people with advanced non-small cell lung cancer that has a specific genetic change (ALK rearrangement). Participants take the targeted drug brigatinib, and if their disease shrinks or stabilizes with few remaining tumors, they also receive local treatments like …

This early-stage trial tests a new oral drug called ORIC-114 combined with an injectable drug, amivantamab, in people with advanced lung cancer that has a specific genetic change (EGFR exon20 insertion). The study aims to find the safest dose and see if the combination shrinks tu…

This early-phase study tests an experimental oral drug called NST-628 in adults with advanced solid tumors that have specific genetic changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 230 partic…

This Phase 2 trial is testing whether combining two immunotherapy drugs (cemiplimab and fianlimab) with radiation can shrink tumors in people with locally advanced non-small cell lung cancer who haven't had treatment yet. The study will enroll 76 participants and measure how well…

This study tests an experimental oral drug called Alintegimod (7HP349) combined with two standard immunotherapies (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, and liver cancers. The trial has two parts: first, finding a safe dose (p…

This study tests whether combining a targeted pill (adagrasib) with precise radiation (SRS) can control brain tumors in people with a specific type of advanced lung cancer (KRAS G12C mutation). About 30 adults with untreated brain metastases will receive both treatments. The main…

This study looks at whether people with lung cancer that has spread to the brain can safely delay radiation therapy. Participants take alectinib, a targeted drug, either alone or with focused radiation. The goal is to see if starting with just the drug keeps the brain cancer unde…

This study tests a new oral drug called VT3989, alone or with other cancer drugs, in people with advanced solid tumors, mesothelioma, or non-small cell lung cancer that hasn't responded to standard treatments. The trial has two phases: first, finding the safest dose, then expandi…

This phase 2 trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy and a tailored radiation plan can help people with stage III non-small cell lung cancer. The study will enroll 35 adults who cannot have surgery. Researchers will track how long the…

This phase 2 trial tests whether adding the drug narlumosbart and precise radiation therapy to standard first-line treatment can help people with advanced non-small cell lung cancer that has spread to the bones. The study will enroll 27 adults who have not had prior systemic ther…

This study tests whether applying a surgical sealant (Progel Platinum) to staple lines during lung cancer surgery can reduce the time patients need a chest tube. About 160 adults having minimally invasive lung lobectomy for non-small cell lung cancer will be randomly assigned to …

This study compares two treatments given before surgery for stage II-IIIA non-small cell lung cancer: immunotherapy (toripalimab) plus radiation versus immunotherapy plus chemotherapy. About 124 adults aged 18-75 will take part. The goal is to see which combination works better a…

This study compares two radiation therapies for people with 4 to 15 brain metastases from cancer: stereotactic radiosurgery (SRS), which is done in 1-2 sessions, versus whole-brain radiotherapy (WBRT), which takes 10 sessions. The goal is to see if SRS offers similar survival wit…

This phase II trial tests whether a drug called BIO 300, made from a soy compound, can prevent severe lung inflammation (pneumonitis) in people with early-stage non-small cell lung cancer who also have interstitial lung disease. About 25 participants will receive BIO 300 along wi…

This early-phase study tests HLX37, a new drug that targets two cancer growth pathways (PD-L1 and VEGF) at once, in people with advanced solid tumors that have spread. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Up to 254 par…

This study tests a drug called repotrectinib in 20 people with a specific type of lung cancer (ROS1-positive NSCLC) that has spread to the brain. The main goal is to see if the drug can shrink or eliminate brain tumors. Participants will take the drug by mouth, and doctors will m…

This early-stage trial is testing a new drug called PRTH-101, alone or with an existing immunotherapy (pembrolizumab), in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The study will enroll about 270 people and focus on safety, do…

This early-stage trial is testing a new drug called TORL-1-23 in about 90 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The drug is an antibody drug conjugate designed to target and kill cancer cells. The main goals are to check safety, find…

This early-phase trial is testing a new drug called NRM-823, alone or with immunotherapy, in people with advanced solid tumors like lung, ovarian, or breast cancer that haven't responded to standard treatments. The study aims to see if the drug is safe and tolerable. About 150 pa…

This phase 2 trial is testing a combination of two immune-boosting antibodies (iparomlimab and tuvonralimab) plus chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. The study will enroll 33 adults who have not had prior treatment.…

This study tests a personalized approach to chemotherapy for people with advanced non-small cell lung cancer (NSCLC) that has spread. Participants have already tried at least one other treatment. The goal is to see if using a tool called OncoChoice to pick the right chemo improve…

This early-phase study tests a new drug called ONO-7428 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the right dose. Participants will receive the drug and be m…

This study tests a new drug called JAB-8263 in adults with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 152 people will take part in this early-phase trial.

This study tests a new treatment for people with a certain type of lung cancer (non-small cell lung cancer) who had surgery but still had cancer cells left. The treatment combines a cell therapy made from the patient's own immune cells (L-TIL) with an immunotherapy drug (tisleliz…

This study tests a new drug called HC010 in people with advanced non-small cell lung cancer that has a specific marker (PD-L1). The goal is to see if the drug can shrink tumors and control the disease. About 50 participants will receive the treatment, and researchers will monitor…

This phase II trial tests whether adding OSE2101 (TEDOPI®) to standard maintenance therapy with cemiplimab can better clear cancer DNA from the blood in people with advanced non-small cell lung cancer. The study enrolls 160 participants who have a specific immune type (HLA-A2 pos…

This study tests a new drug called YL202 in people with advanced solid tumors, including lung, breast, and head/neck cancers. The goal is to see if the drug can shrink tumors and control the disease. About 200 participants will receive the drug, and researchers will monitor safet…

This study is testing a combination of the immunotherapy drug Sugemalimab and standard chemotherapy as a first treatment for people with advanced non-small cell lung cancer (NSCLC) that has spread. The goal is to see how well this combo works in real-world clinics, not just in co…

This study tests whether a special low-calorie, plant-based diet that mimics fasting can help patients with stage IV non-small cell lung cancer respond better to maintenance immunotherapy. Sixty-six participants will follow the diet for three cycles while continuing their regular…

This early-stage trial tests a new treatment called T3011, a modified virus injected directly into tumors, for people with advanced solid cancers like melanoma, lung cancer, or sarcoma. The study will also test T3011 combined with the immunotherapy drug pembrolizumab (Keytruda). …

This study is for people with advanced non-small cell lung cancer (stage IIIB/C-IV) who cannot tolerate standard chemoradiation. It tests a treatment plan of platinum-based chemotherapy, followed by a special type of radiation and the immunotherapy drug Tislelizumab. The goal is …

This study is for people with advanced non-small cell lung cancer that has stopped responding to a type of targeted therapy called third-generation EGFR TKIs. Researchers want to see if giving chemotherapy first, followed by a newer targeted drug called befotertinib, can help con…

This study is testing a blood test called TheraSure CNI-Monitor in 170 people with advanced lung cancer (NSCLC) who are receiving immunotherapy. The test looks for tiny bits of tumor DNA in the blood to see if the cancer is responding to treatment or getting worse. The goal is to…

This study is testing whether a special PET scan using a tracer called 68Ga-MY6349 can predict how well a targeted therapy (Trop2-ADC) works in people with advanced non-small cell lung cancer (NSCLC). Fifty adult patients will receive the scan before and during treatment. The goa…

This study tests whether using CPAP or BiPAP breathing machines can reduce tumor movement during radiation therapy for lung cancer, esophageal cancer, or lymphoma. About 31 adults with advanced but treatable cancers will try these machines during treatment. The goal is to see if …

This study compares a new radiation technique called lattice radiation therapy (LRT) to standard stereotactic body radiation therapy (SBRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better and helps the immune system f…

This study looks at how the body's metabolism might influence whether immunotherapy drugs work in people with non-small cell lung cancer. Researchers will collect and analyze tissue samples from 150 patients to compare those who respond to treatment with those who don't. The goal…

This observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…

This study looks at whether features on CT scans can predict how well non-small cell lung cancer responds to chemoimmunotherapy given before surgery. Researchers will compare CT images taken before and after treatment with the actual results from surgery. The goal is to develop a…

This observational study follows 100 adults with metastatic non-small cell lung cancer who have certain EGFR gene mutations and are receiving amivantamab plus platinum-based chemotherapy through an early access program. Researchers will collect medical data to see how long the tr…

This study looks at whether a computer model can predict how well non-small cell lung cancer responds to chemotherapy and immunotherapy given before surgery. Researchers will collect data from 500 participants to build and test this prediction tool. The goal is to improve treatme…

This study is for people with non-small cell lung cancer who are about to start immunotherapy. Researchers want to see if the body makes antibodies against the immunotherapy drugs. By collecting blood samples from 270 participants, they hope to learn more about how the immune sys…

This study is looking at genetic differences between the original lung cancer tumor and where it has spread in the body. Researchers will analyze DNA from stored tumor samples of 25 adults with non-small cell lung cancer. The goal is to better understand how lung cancer spreads, …

This study looks at whether people with early-stage lung cancer (stage IA2 to II) who have no detectable cancer DNA in their blood after surgery can safely skip additional treatments like chemotherapy. Instead, they would be closely monitored with regular blood tests and scans. T…

This observational study is collecting blood samples and medical images from 200 people with several types of solid tumors (like lung, head and neck, and esophageal cancers) who are receiving immunotherapy and radiation as part of their standard care. Researchers want to see if c…